TGA blood glucose advisory
November 19, 2010
THE Therapeutic Goods
Administration has reissued its
advisory on portable blood glucose
meters using the enzyme glucose
dehydrogenase pyrroloquinoline
quinone (GDH-PQQ), warning of
potential adverse consequences
because they can provide false high
readings if they are used in the
presence of galactose, xylose and
maltose.
The TGA initially warned about
the possible issues about
inteference between extraneal
peritoneal dialysis solution and the
Advantage II blood glucose test
strips used with Accu-Chek and
Accu-Trend monitors in 2005.
Since then “further adverse
events have been reported in
Australia and worldwide” and
although the overall rate of
incidence has not markedly
increased, the updated advisory is
being issued as a precaution.
The TGA has highlighted items
sold in Australia which use the
GDH-PQQ technology including
Abbott Freestyle products and
Roche Diagnostics Accu-chek strips
and sensors.
Drug therapies which can
interfere with the systems include
Icodextrin, Orencia, Octagam,
Gamimune, Adept and some
radioimmunotherapy agents.
Patients undergoing treatment
with these substances are warned
to use different types of blood
glucose monitoring systems.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Nov 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Nov 10
